Weighed down by safety concerns of JAK portfolio, Pfizer hatches a deal to go a different direction in rheumatoid arthritis
Days after conceding that its blockbuster JAK inhibitor flunked a post-marketing safety study, Pfizer has signed off on a brand new approach to rheumatoid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.